ArticleFrontiers in microbiology2025
Modified Pulsatilla decoction ameliorates ulcerative colitis by affecting gut microbiota and metabolite profiles.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mechanisms of traditional Chinese medicine in enhancing the efficacy and reducing the toxicity of immune checkpoint inhibitorsJournal of enzyme inhibition and medicinal chemistry · 2026Review
- Synergistic effects of fecal microbiota transplantation and andrographolide on gut microbiota modulation in dextran sulfate sodium-induced colitis in mice.Frontiers in microbiology · 2026Article
- Orally administered gallic acid nanoparticles adhere to intestine via in-situ gelation for enhanced UC treatment.Materials today. Bio · 2025Article
- Modified Pulsatilla decoction alleviates DSS-induced colitis in mice by modulating gut microbiota and promoting IL-10 and IL-22 expression.BMC complementary medicine and therapies · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the therapeutic effects of a specific modified Pulsatilla decoction (MPD) on ulcerative colitis (UC) in mice, 32 male Balb/c mice were randomly assigned to four groups: Control, Model, High-dose (H-dose), and Low-dose (L-dose), with eight mice per group. All groups except the Control group were administered 3% dextran sulfate sodium (DSS) in their drinking water for 7 days to induce acute UC. The H-dose group and L-dose group mice were gavaged, respectively, with different concentrations of MPD, while the Control group and Model group received the same amount of steriled water by gavage. Clinical symptoms of the mice were observed and recorded throughout the study. Subsequently, pathological sections of the colon tissues were prepared, and 16S rRNA high-throughput sequencing and metabolomics analysis were conducted on the intestinal contents. The results indicated that MPD improved the structure and morphology of colon tissue, significantly reducing inflammatory damage in DSS-treated mice. Furthermore, MPD alleviated DSS-induced intestinal injury by enhancing the abundance of beneficial intestinal probiotics, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.